UCT 01 097
Alternative Names: UCT-01-097Latest Information Update: 28 Apr 2024
At a glance
- Originator 1200 Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase 1 inhibitors; Mitogen-activated protein kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease) in USA (PO)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Monotherapy) in USA (PO)
- 29 Feb 2024 1200 Pharma terminates phase-I clinical trial in Solid tumours (Combination therapy, Late-stage disease) in USA (PO) due to strategic business reasons, the decision to stop the study was not connected to any safety concerns, or new risk associated with the study product (NCT04761601)